NfL is a well-studied biomarker for neuroaxonal injury with wide applicability to different neurological disorders, the firm noted, adding that measurement of the protein in serum and plasma was first enabled with the release of its research-use-only (RUO) Simoa NfL kit several years ago.

"Assessment and monitoring of brain health is incredibly difficult and typically performed in limited fashion by surgery or imaging," Masoud Toloue, CEO of Quanterix, said in a statement. "We see NfL as not only an important marker for neurodegenerative disease but also a critical measure of brain-related side effects during chemotherapy, CAR T-cell therapy, and stroke."

The company expects the launch of its CLIA-validated NfL blood test will enable future therapeutic trials and advance clinical care, he added.

Severe COVID-19 outweighs rare post-vaccination myocarditis risk
Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital investigated the immune response of young adults who developed myocarditis...

Novel peptide targets Alzheimer’s disease years before symptoms
New research demonstrates a novel synthetic peptide’s ability to selectively detect and neutralize an early molecular trigger of Alzheimer’s disease,...

Nerve cell discovery may improve neurodegenerative disease treatments
Researchers at King’s College London and the University of Bath have made a nerve cell discovery that may improve treatment options for patients with...

11 new developments in cell and gene therapy
There have been a number of recent developments in the cell and gene therapy field. Bruce Carlson, publisher of Cell and Gene Therapy Business Outlook,...